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Background
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and 
severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing 
phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.
Methods
We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 
6 to 12 weeks of age at the time of the first vaccination in conjunction with Ex-
panded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. 
Vaccine efficacy against the first or only episode of clinical malaria during the 
12 months after vaccination, a coprimary end point, was analyzed with the use of 
Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy 
against severe malaria, safety, and immunogenicity were also assessed.
Results
The incidence of the first or only episode of clinical malaria in the intention-to-treat 
population during the 14 months after the first dose of vaccine was 0.31 per person-
year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a 
vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine effi-
cacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine ef-
ficacy against severe malaria was 26.0% (95% CI, −7.4 to 48.6) in the intention-to-
treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. 
Serious adverse events occurred with a similar frequency in the two study groups. 
One month after administration of the third dose of RTS,S/AS01, 99.7% of children 
were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 
209 EU per milliliter (95% CI, 197 to 222).
Conclusions
The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest pro-
tection against both clinical and severe malaria in young infants. (Funded by 
 Glaxo SmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S 
ClinicalTrials.gov number, NCT00866619.)
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Considerable gains have been achieved in malaria control during the past decade.1,2 Nonetheless, malaria remains a 
major public health concern. In 2010, an estimat-
ed 216 million cases of malaria and 655,000 
malaria-related deaths occurred, with the vast 
majority of deaths occurring in African children.1
The RTS,S/AS01 candidate malaria vaccine tar-
gets the pre-erythrocytic stage of the Plasmodium 
falciparum parasite. It was developed to reduce 
clinical and severe malaria in African children. 
Ideally, it would be administered through the 
well-established Expanded Program on Immuni-
zation (EPI).
In 2011, we reported the results for the first 
coprimary end point from an ongoing phase 3 
trial, which showed that during 12 months of 
follow-up, RTS,S/AS01 had an efficacy against 
clinical and severe malaria of 55.8% (97.5% con-
fidence interval [CI], 50.6 to 60.4) and 47.3% (95% 
CI, 22.4 to 64.2), respectively, among children 5 to 
17 months of age at enrollment (per-protocol 
analysis).3 Vaccine efficacy against severe malaria 
among children 6 to 12 weeks of age and those 
5 to 17 months of age combined was 34.8% 
(95% CI, 16.2 to 49.2) during an average of 11 
months of follow-up (range, 0 to 22). We now 
report on the second coprimary end point from 
the same trial: efficacy against clinical malaria 
during 12 months of follow-up among infants 
6 to 12 weeks of age at enrollment, when RTS,S/
AS01 was coadministered with EPI vaccines.
Me thods
STUDY DESIGN
Details of the study methods have been described 
previously3-7 and are provided in the Supplemen-
tary Appendix and the study protocol, both of 
which are available with the full text of this ar-
ticle at NEJM.org. This phase 3, randomized, 
controlled, double-blind trial is being conducted 
at 11 centers in 7 African countries with a range 
of malaria-transmission intensity (Fig. S1 in the 
Supplementary Appendix). The trial is designed 
to evaluate vaccine efficacy, safety, and immuno-
genicity for 32 months after the first dose of 
study vaccine in children 6 to 12 weeks of age or 
5 to 17 months of age at enrollment. The trial 
includes three study groups in each age category: 
infants who received three doses of RTS,S/AS01 
administered at 1-month intervals and a booster 
dose 18 months after the third dose, infants who 
received three doses of RTS,S/AS01 at 1-month in-
tervals without a booster dose, and a control group 
of infants who received a non-malaria compara-
tor vaccine. The analysis described in this report 
combines the first two groups (referred to as the 
RTS,S/AS01 group) and compares this group with 
the control group6 14 months after the first dose 
of vaccine administered in children 6 to 12 weeks 
of age (Fig. S2 in the Supplementary Appendix). 
The trial protocol was approved by all relevant 
ethics review boards and national regulatory au-
thorities (Tables S1A and S1B in the Supplemen-
tary Appendix). Written informed consent was 
obtained from the children’s parents or guard-
ians. The study was undertaken in accordance 
with Good Clinical Practice guidelines.8
STUDY OVERSIGHT
The trial was sponsored by GlaxoSmithKline Bio-
logicals (GSK), the vaccine developer and manu-
facturer, and funded by both GSK and the Pro-
gram for Appropriate Technology in Health (PATH) 
Malaria Vaccine Initiative, which received a grant 
from the Bill and Melinda Gates Foundation. 
All study centers received study grants from the 
Malaria Vaccine Initiative, which also provided 
funding for authors’ travel and accommodations 
related to this trial. All the authors reviewed all 
manuscript drafts, approved the final version of 
the manuscript, and made the decision to submit 
it for publication. No GSK authors were involved in 
the collection or analysis of the data; the analysis 
was performed by an independent statistician. The 
authors had full access to the results. The authors 
remain unaware of study-group assignments in 
this ongoing trial and do not have access to the 
raw data at this point. Details of the contributions 
of all the authors to the study are available in the 
Supplementary Appendix. The Clinical Trials Part-
nership Committee and Writing Group vouch for 
the completeness and accuracy of the data pre-
sented and for the fidelity of this report to the 
study protocol.
RANDOMIZATION AND VACCINATION
From December 2009 through January 2011, a to-
tal of 6537 infants 6 to 12 weeks of age were ran-
domly assigned to one of the three study groups 
in a 1:1:1 ratio. Three doses of the RTS,S/AS01 or 
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the comparator vaccine, meningococcal sero-
group C conjugate vaccine (Menjugate, Novartis), 
were coadministered with EPI vaccines according 
to the World Health Organization EPI schedule.9 
EPI vaccines comprised a diphtheria–tetanus–
whole-cell pertussis–hepatitis B–Hemo phil us in-
fluenzae type b pentavalent vaccine (Tritanrix HepB 
Hib, GSK) and an oral poliovirus vaccine con-
taining serotypes 1, 2, and 3 (Polio Sabin, GSK). 
The study and pentavalent vaccines were admin-
istered intramuscularly at different protocol-speci-
fied injection sites.
SURVEILLANCE FOR CLINICAL AND SEVERE MALARIA
Passive surveillance for malaria began at the time 
of the first vaccination. Parents or guardians of 
the study participants were encouraged to seek 
care at a health facility if the child had any signs 
of illness, and transportation was facilitated. All 
participants who presented to a study facility 
with reported or documented fever during the 
previous 24 hours were evaluated for malaria.
The primary efficacy end point for this analy-
sis was the incidence of clinical malaria, defined 
as an illness in a child who was brought to a study 
facility with an axillary temperature of 37.5°C or 
higher and P. falciparum asexual para sitemia at a 
density of more than 5000 parasites per cubic 
millimeter or a case of malaria meeting the pri-
mary case definition of severe malaria (Table S2 
in the Supplementary Appendix). Different para-
site thresholds were used for secondary case 
definitions (Table 1). Participants who were hos-
pitalized were evaluated for severe malaria on 
the basis of a protocol-defined algorithm (Table 
S3 in the Supplementary Appendix).4,10
SAFETY SURVEILLANCE
Data regarding serious adverse events were re-
corded by means of passive surveillance begin-
ning after the first dose of vaccine. Verbal autop-
sies were conducted for deaths that occurred 
outside study facilities.11 Information was col-
lected on all unsolicited reports of adverse events 
that occurred within 30 days after vaccination 
and on reactogenicity (pain, swelling, redness at 
the injection site, drowsiness, fever, irritability or 
fussiness, or loss of appetite) within 7 days after 
vaccination among the first 200 participants en-
rolled at each center. Symptom intensity was as-
sessed with the use of standardized methods 
(Table S4 in the Supplementary Appendix). Infor-
mation on related adverse events within 30 days 
after vaccination was collected for all partici-
pants. Study clinicians used clinical judgment to 
decide whether an adverse event was likely to be 
related to the vaccine. In an analysis of previous 
RTS,S studies, rash was observed more frequently 
in children vaccinated with RTS,S than in con-
trols.12 Rashes and mucocutaneous diseases oc-
curring within 30 days after vaccination and sei-
zures occurring within 7 days after vaccination 
were reported according to Brighton Collabora-
tion guidelines13,14 (see the Methods section in 
the Supplementary Appendix).
IMMUNOGENICITY
Anti-circumsporozoite antibodies were measured 
by means of enzyme-linked immunosorbent 
 assay15 in the first 200 infants enrolled at each 
study center at screening and 1 month after dose-3. 
An antibody titer of 0.5 EU per millimeter or 
greater was considered to be positive.
LABORATORY AND RADIOLOGIC PROCEDURES
Laboratory and radiologic procedures have been 
reported previously5 and are described in the 
Supplementary Appendix.
STATISTICAL ANALYSIS
The statistical methods have been described in 
detail previously.3,7 We used Cox regression mod-
els (1 minus hazard ratio) to evaluate vaccine ef-
ficacy against the first or only episode of clinical 
malaria, using the study center as a stratification 
factor that allowed for differential baseline haz-
ards. For the coprimary end point, vaccine effi-
cacy against clinical malaria during 12 months 
of follow-up in the two age categories, 97.5% 
confidence intervals were used, ensuring an 
overall two-sided alpha level of 5%. The propor-
tionality of hazards was evaluated by means of 
Schoenfeld residuals and models, including time-
varying covariates. Secondary analyses, which 
included evaluations based on other case defini-
tions and an analysis including multiple episodes 
of clinical malaria, were performed with the use 
of negative binomial regression. Vaccine efficacy 
against severe malaria was defined as 1 minus 
the risk ratio and is presented with 95% confi-
dence intervals and Fisher’s exact P values.
Primary analyses of vaccine efficacy were 
based on the per-protocol population, which in-
cluded all participants who received three doses 
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of a study vaccine coadministered with EPI vac-
cines and who were included in efficacy surveil-
lance, starting 14 days after the third dose of a 
study vaccine. The modified intention-to-treat 
population included all participants who received 
at least one dose of a study vaccine. In the ad-
justed analyses, vaccine efficacy was adjusted 
for study center and distance to the nearest out-
patient facility (≤5 km vs. >5 km). Data were 
censored 14 months after the first dose of vac-
cine, or at the date of emigration, withdrawal of 
consent, or death.
Serious adverse events were coded from clini-
cian-assigned diagnoses according to the pre-
ferred terms of the Medical Dictionary for Regulatory 
Activities16 and were based on available clinical 
and laboratory evidence.
The primary analysis of immunogenicity was 
based on the per-protocol population. Anti-cir-
cumsporozoite antibody titers were plotted and 
evaluated after the third dose of a study vaccine 
on the basis of seropositivity levels and geomet-
ric mean titers.
R esult s
STUDY POPULATION
In total, 6537 infants 6 to 12 weeks of age were 
enrolled; 6003 (91.8%) were included in the per-
protocol analysis (Fig. 1, and Fig. S3 in the Sup-
plementary Appendix). Baseline demographic 
characteristics were similar in the two study 
groups (Table S5 in the Supplementary Appen-
dix). The numbers of participants and malaria 
episodes according to study center are shown in 
Table S6 in the Supplementary Appendix. As ex-
pected, the majority of malaria episodes were 
reported by centers in areas with the highest 
transmission; 43.5% of all clinical malaria epi-
sodes were reported by two high-transmission 
sites in western Kenya. These two sites, combined 
with the site in Nanoro, Burkina Faso (where 
transmission is high but seasonal), accounted for 
72.6% of clinical malaria episodes in this analy-
sis. The rate of use of insecticide-treated nets was 
85.8% overall and was similar in the two study 
groups. Indoor residual spraying was conducted 
as a public health intervention at four study cen-
ters; at those centers, spraying coverage was low 
(Table S7 in the Supplementary Appendix).
VACCINE EFFICACY AGAINST CLINICAL AND SEVERE 
MALARIA
In the per-protocol population, the incidence of a 
first or only episode of clinical malaria meeting 
the primary case definition during 12 months of 
follow-up was 0.37 per person-year in the RTS,S/
AS01 group and 0.48 per person-year in the con-
trol group, for a vaccine efficacy of 31.3% (97.5% 
CI, 23.6 to 38.3). Kaplan–Meier curves are shown 
in Figures 2A and 2B. Vaccine efficacy was not 
constant over time (P<0.001 by Schoenfeld re-
siduals), with efficacy higher at the beginning 
than at the end of the follow-up period (Table S8 
in the Supplementary Appendix). Vaccine effica-
cy against all clinical malaria episodes was 32.9% 
(95% CI, 26.3 to 38.8). Estimates of efficacy 
against clinical malaria were consistent across 
all case definitions and in both adjusted and 
intention-to-treat analyses (Table 1).
At least one episode of severe malaria occurred 
in 58 of 3995 infants (1.5%) in the RTS,S/AS01 
group and in 46 of 2008 infants (2.3%) in the 
control group, for a vaccine efficacy of 36.6% 
(95% CI, 4.6 to 57.7) in the per-protocol popula-
tion. In the intention-to-treat population, at least 
one episode of severe malaria occurred in 77 of 
4358 infants (1.8%) in the RTS,S/AS01 group and 
in 52 of 2179 infants (2.4%) in the control 
group, for a vaccine efficacy of 26.0% (95% CI, 
−7.4 to 48.6) (Table 1, and Tables S15 and S16 in 
the Supplementary Appendix).
SAFETY
Serious Adverse Events
Serious adverse events were reported in 17.9% (95% 
CI, 16.8 to 19.1) of recipients of the RTS,S/AS01 
vaccine and in 19.2% (95% CI, 17.6 to 20.9) of 
recipients of the meningococcal vaccine (Table 2, 
and Table S9 in the Supplementary Appendix). A 
total of 94 infants died: 66 of 4358 infants (1.5%; 
95% CI, 1.2 to 1.9) in the RTS,S/AS01 group and 
28 of 2179 infants (1.3%; 95% CI, 0.9 to 1.9) in the 
control group. Causes of death were similar in 
the two groups; none of the deaths were thought 
to be related to vaccination (Table S10 in the Sup-
plementary Appendix). Serious adverse events that 
were considered to be related to a study vaccine 
occurred in 7 infants: 4 of the 4358 infants in the 
RTS,S/AS01 group and 3 of the 2179 infants in 
the control group; 4 events (2 in each group) 
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6537 Underwent randomization and
received study vaccine
545 Were not eligible
364 Did not meet criteria
2 Died
84 Withdrew consent
65 Moved or were lost to follow-up
30 Had other reasons
4358 Received dose 1 of RTS,S/AS01
(ITT population)
2179 Received dose 1 of control
vaccine (ITT population)
213 Did not complete
vaccination
27 Died or withdrew
for medical
reasons
47 Had consent with-
drawn or parent or
guardian declined 
to participate
84 Moved or were 
lost to follow-up
55 Had other reasons
503 Did not
complete
visit 16
37 Died
16 Had consent
withdrawn
450 Moved or
were lost to
follow-up
260 Did not
complete
visit 16
21 Died
4 Had consent
withdrawn
235 Moved or
were lost to
follow-up
150 Were not included 
in the per-protocol
analysis
7 Did not meet 
inclusion criteria
113 Were out of
interval for dose
regimen
16 Were lost to 
follow-up after
dose 3
14 Had other
reasons
82 Were not included 
in the per-protocol
analysis
5 Did not meet 
inclusion criteria
64 Were out of
interval for dose
regimen
3 Were lost to 
follow-up after
dose 3
10 Had other
reasons
89 Did not complete
vaccination
9 Died or withdrew 
for medical
reasons
20 Had consent with-
drawn or parent or
guardian declined 
to participate
38 Moved or were 
lost to follow-up
22 Had other reasons
4235 Received dose 2 2134 Received dose 2
4145 Received dose 3 2090 Received dose 3
3642 Attended visit 16
(12 mo after dose 3)
1830 Attended visit 16
(12 mo after dose 3)
3995 Were included in the
per-protocol population
2008 Were included in the
per-protocol population
7082 Infants were assessed for eligibility
Figure 1. Enrollment of Infants 6 to 12 Weeks of Age.
ITT denotes intention to treat.
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were episodes of fever for which infants were hos-
pitalized for investigation. One infant (in the con-
trol group) had anaphylaxis, one infant (in the 
RTS,S/AS01 group) had a suspected injection-site 
infection related to the pentavalent vaccine, and 
one infant (in the RTS,S/AS01 group) had repeat-
ed febrile seizures associated with a respiratory 
infection. The frequency of seizures within 7 days 
after vaccination, reported previously, was simi-
lar in the two study groups.3
Meningitis of any cause was reported as a 
serious adverse event in 11 infants: 9 of the 4358 
infants in the RTS,S/AS01 group and 2 of the 
2179 infants in the control group (relative risk in 
the RTS,S/AS01 group, 2.3; 95% CI, 0.5 to 10.4). 
A pathogen was identified for 7 of the events 
(salmonella in 3 episodes of meningitis and 
pneumococcus in 4 episodes). The 4 remaining 
events, with no pathogen identified, were re-
ported by a single study center (3 episodes of 
meningitis in the RTS,S/AS01 group and 1 epi-
sode in the control group). Of the 11 episodes of 
meningitis, 2 were new (1 due to pneumococcus 
and 1 due to salmonella); the 9 other episodes have 
been reported previously.3 Investigator-driven 
medical review of previously reported meningitis 
episodes led to reclassification of 1 episode as 
an episode of pneumonia and reclassification of 
4 episodes without cause as 2 episodes of pneu-
mococcal meningitis and 2 of salmonella men-
ingitis. Four of the episodes of meningitis oc-
curred within 30 days after vaccination.
Adverse Events
Unsolicited reports of adverse events within 30 days 
after vaccination were recorded with similar fre-
quency in the RTS,S/AS01 group (79.4%; 95% CI, 
77.2 to 81.5) and in the control group (81.3%; 
95% CI, 78.3 to 84.1). No clinically important 
imbalances were observed (Table S11A in the 
Supplementary Appendix). Information on unso-
licited reports of adverse events related to the 
vaccine or leading to withdrawal within 30 days 
after vaccination is shown in Table S11B in the 
Supplementary Appendix. The frequency of solic-
ited reports of local symptoms was similar 
among infants who received the RTS,S/AS01 vac-
cine and among those who received the menin-
gococcal vaccine and was lower than that ob-
served with the pentavalent vaccine (Table S13 in 
the Supplementary Appendix). Systemic reacto-
genicity was higher in the RTS,S/AS01 group 
than in the control group (Fig. 3, and Table S12 
in the Supplementary Appendix). Postvaccination 
fever was reported after 30.6% of doses (95% CI, 
29.2 to 32.0) in the RTS,S/AS01 group and after 
21.1% of doses (95% CI, 19.4 to 22.8) in the con-
trol group. A temperature higher than 39°C was 
reported after less than 1% of doses. The inci-
dence of mucocutaneous disease was similar in 
the two study groups (Table S14 in the Supplemen-
tary Appendix).
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Figure 2. Cumulative Incidence of a First or Only Episode of Clinical Malaria 
(Primary Case Definition).
The cumulative incidence of clinical malaria in infants 6 to 12 weeks of age 
at enrollment is shown for the 12 months of follow-up after the third dose of 
a study vaccine in the per-protocol population (Panel A) and for the 14 months 
of follow-up after the first dose of vaccine in the intention-to-treat population 
(Panel B).
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IMMUNOGENICITY
Before vaccination, 34.3% and 35.2% of infants in 
the RTS,S/AS01 and control groups, respectively, 
were positive for anti-circumsporozoite antibodies 
but at low titers (Fig. S4 in the Supplementary 
Appendix). One month after the third dose of the 
study vaccine, 99.7% of infants in the RTS,S/AS01 
group were positive for anti-circumsporozoite an-
tibodies, with a geometric mean titer of 209 EU 
per milliliter (95% CI, 197 to 222).
Discussion
This phase 3 trial showed that in young infants, 
the RTS,S/AS01 candidate vaccine provided mod-
est protection against malaria when coadminis-
tered with EPI vaccines. The efficacy of RTS,S/
AS01 reported here is lower than that observed in 
a phase 2 trial involving infants at three of the 
phase 3 trial sites, in which RTS,S/AS01 was co-
administered with EPI vaccines. In that trial, geo-
Table 2. Serious Adverse Events in Infants 6 to 12 Weeks of Age at Enrollment during 14 Months after the First Dose 
of Vaccine (Intention-to-Treat Population).
Variable
RTS,S/AS01 Vaccine
(N = 4358)
Control Vaccine 
(N = 2179)
No. of  
Infants % (95% CI)
No. of  
Infants % (95% CI)
Serious events in all infants
≥1 Serious adverse event 782 17.9 (16.8–19.1) 419 19.2 (17.6–20.9)
≥1 Serious adverse event, excluding malaria 760 17.4 (16.3–18.6) 407 18.7 (17.1–20.4)
≥1 Fatal serious adverse event* 66 1.5 (1.2–1.9) 28 1.3 (0.9–1.9)
≥1 Serious adverse event related to vaccine 4 0.1 (0.0–0.2) 3 0.1 (0.0–0.4)
≥1 Serious adverse event within 30 days  
after vaccination
192 4.4 (3.8–5.1) 96 4.4 (3.6–5.4)
Events with an incidence ≥0.5%†
Pneumonia 302 6.9 (6.2–7.7) 152 7.0 (5.9–8.1)
Gastroenteritis 260 6.0 (5.3–6.7) 139 6.4 (5.4–7.5)
Malaria 184 4.2 (3.6–4.9) 115 5.3 (4.4–6.3)
Anemia 90 2.1 (1.7–2.5) 58 2.7 (2.0–3.4)
Febrile convulsion 82 1.9 (1.5–2.3) 46 2.1 (1.5–2.8)
Bronchiolitis 28 0.6 (0.4–0.9) 21 1.0 (0.6–1.5)
Convulsion 41 0.9 (0.7–1.3) 19 0.9 (0.5–1.4)
Bronchopneumonia 35 0.8 (0.6–1.1) 20 0.9 (0.6–1.4)
Upper respiratory tract infection 36 0.8 (0.6–1.1) 19 0.9 (0.5–1.4)
Salmonella sepsis 26 0.6 (0.4–0.9) 16 0.7 (0.4–1.2)
Malnutrition 29 0.7 (0.4–1.0) 7 0.3 (0.1–0.7)
Sepsis 26 0.6 (0.4–0.9) 10 0.5 (0.2–0.8)
HIV infection‡ 27 0.6 (0.4–0.9) 9 0.4 (0.2–0.8)
Enteritis 11 0.3 (0.1–0.5) 12 0.6 (0.3–1.0)
Urinary tract infection 16 0.4 (0.2–0.6) 10 0.5 (0.2–0.8)
Measles 20 0.5 (0.3–0.7) 7 0.3 (0.1–0.7)
Pyrexia 15 0.3 (0.2–0.6) 11 0.5 (0.3–0.9)
* More than one fatal serious adverse event could be attributed to a single infant if there was more than one underlying 
cause of death (e.g., meningitis and sepsis).
† Events are listed according to the preferred terms in the Medical Dictionary for Regulatory Activities.
‡ HIV denotes human immunodeficiency virus.
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metric mean titers of anti-circumsporozoite anti-
bodies after vaccination were similar to those 
measured here, but vaccine efficacy against clini-
cal malaria was 61.6% (95% CI, 35.6 to 77.1).17 
Although we wish to avoid overinterpretation of 
the results of this previously reported small 
phase 2 trial with wide confidence intervals, it is 
notable that this higher estimate of efficacy 
comes from a study conducted at sites in areas 
with low-to-moderate malaria transmission. It is 
possible that the pooled estimate across the 11 
centers in the phase 3 trial obscures differences 
in vaccine efficacy according to transmission in-
tensity and that these two sets of results are com-
patible with each other.
The efficacy of the RTS,S/AS01 vaccine re-
ported here is also lower than that reported previ-
ously among older children recruited for this trial 
at the same study centers.3 A likely explanation 
for the lower vaccine efficacy among infants is an 
age-dependent differential immune response to 
the vaccine. This concept is supported by the lower 
anti-circumsporozoite antibody titers observed in 
infants (geometric mean titer, 209 EU per millili-
ter; 95% CI, 197 to 222) as compared with titers 
in older children (621 EU per milliliter; 95% CI, 
592 to 652), reported previously.3 Although the 
titer of anti-circumsporozoite antibodies is not 
an established correlate of the level of protection, 
an association with efficacy has been observed in 
several trials.17-21 Infants may have mounted a 
lower immune response than older children ow-
ing to coadministration of RTS,S/AS01 with rou-
tine EPI vaccines, an inhibitory effect of mater-
nally derived anti-circumsporozoite antibodies, an 
absence of priming with hepatitis B vaccine or 
with P. falciparum infection, or the infant’s imma-
ture immune system.
Coadministration of RTS,S/AS01 with the pen-
tavalent vaccine and the oral poliovirus vaccine 
might have resulted in immune interference and 
contributed to the lower anti-circumsporozoite 
antibody titers in the younger infants. Two phase 2 
studies have explored the immunologic response 
to the related RTS,S/AS02 vaccine, either when 
co administered with a diphtheria–tetanus–pertus-
sis–hepatitis B vaccine or when given 2 weeks 
afterward. The geometric mean titer of anti-
circumsporozoite antibodies was lower when vac-
cines were coadministered than when they were 
staggered (70 EU per milliliter [95% CI, 54 to 90] 
vs. 200 EU per milliliter [95% CI, 151 to 265]).20,21 
However, vaccine efficacy against infection was 
similar in the two trials (65.2% [95% CI, 20.7 to 
84.7] during 6 months after vaccination and 65.9% 
[95% CI, 42.6 to 79.8] during 3 months after vac-
cination, respectively).
An absence of priming with hepatitis B vac-
cine or with P. falciparum infection may also have 
contributed to the lower anti-circumsporozoite 
antibody titers. In this trial, infants simultaneously 
received a hepatitis B surface antigen (HBsAg)–
containing combination vaccine and the RTS,S 
vaccine, which contains HBsAg fused as a carrier 
protein to the circumsporozoite protein. Immune 
interference on concurrent administration of sim-
ilar protein components has been described.22 
In contrast, in older children vaccinated against 
hepatitis B, memory T-cell reactivation may have 
enhanced the anti-circumsporozoite antibody re-
sponse to RTS,S/AS01.22 One study showed a 
tendency toward higher anti-circumsporozoite 
antibody responses in children who had been 
vaccinated against hepatitis B than in children 
who had not previously received hepatitis B vac-
cine.23 Maternally derived antibodies can inter-
fere with the immune response in young infants; 
such interference is common with live vaccines, 
such as the measles vaccine, but can also occur 
with some protein vaccines.24,25 Similarly, pas-
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Figure 3. Incidence of Solicited Reports of Adverse Events 
during the 7-Day Postvaccination Period after Each Dose 
(Intention-to-Treat Population).
Solicited reports of adverse events during the 7-day 
postvaccination period were recorded and analyzed in 
the first 200 infants enrolled at each study site.
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sively acquired antibodies to either HBsAg or the 
circumsporozoite components of the RTS,S/AS01 
vaccine might have suppressed immune respons-
es. Finally, although most protein vaccines and 
polysaccharide–protein conjugate vaccines are 
immunogenic in young infants, improved immu-
nogenicity and efficacy have often been achieved 
when vaccination has extended beyond the first 
few months of life.22,26,27
As previously reported in older children,3 sta-
tistical models indicated nonproportionality of 
hazards over time. This could be due to waning 
vaccine efficacy, differential acquisition of natu-
ral immunity, or other factors that may influ-
ence the model,28 such as heterogeneity of expo-
sure, the vaccine effect at the individual level, or 
both.29,30 If vaccine efficacy does wane, this 
might contribute to the lower observed efficacy 
among infants than among older children, espe-
cially because young infants may be less sus-
ceptible to malaria in the immediate postvacci-
nation period owing to maternally acquired 
immunity, fetal hemoglobin, lower exposure, and 
other factors.31
The 11 sites of the phase 3 trial cover a wide 
range of malaria-transmission intensity. The in-
clusion of sites in high-transmission or seasonal-
transmission areas and the large proportion of 
cases of severe and clinical malaria from these 
sites might have contributed to the lower vaccine 
efficacy among infants in this trial than in ear-
lier trials involving infants. The implications of 
the large representation of malaria episodes 
from high-transmission areas may become ap-
parent when site-specific data are analyzed at a 
later date, as specified by the protocol. Esti-
mates of site-specific vaccine efficacy and the 
corresponding estimates of clinical or severe 
malaria episodes averted will help to determine 
what role this vaccine might have in malaria 
control. Exploration of factors that might affect 
vaccine efficacy, including the effect of maternal 
antibodies, the role of immune interference by 
EPI vaccines, the effect of the RTS,S/AS01 boost-
er, and status with respect to previous exposure 
to P. falciparum parasites, will provide crucial in-
formation for the further development of this 
vaccine and for other malaria vaccines under 
development.32
Overall, fatal, or vaccine-related serious ad-
verse events were balanced between the study 
groups. In the previous analysis, which included 
infants and older children, the incidence of men-
ingitis was imbalanced between the RTS,S/AS01 
and control groups.3 The imbalance remains, but 
we now have clarified that the majority of cases 
had a bacterial cause. We will continue to mon-
itor the incidence of meningitis throughout the 
trial. The imbalance in the incidence of rash, 
observed in previous RTS,S studies,12,33 was not 
confirmed in this larger trial.
This phase 3 trial shows efficacy of the 
RTS,S/AS01 vaccine. Data from the remainder of 
this trial and additional studies in progress will 
contribute to the understanding of the complex 
interplay among the intensity of exposure to ma-
laria, the immune response, and vaccine efficacy.
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